Sodium tanshinone IIA sulfonate inhibits hypoxia-induced enhancement of SOCE in pulmonary arterial smooth muscle cells via the PKG-PPAR-γ signaling axis

American Journal of Physiology - Cell Physiology

Volumn 311, Issue 1, 2016, Pages C136-C149

  Jiang, Qian ^a   Lu, Wenju ^a   Yang, Kai ^a   Hadadi, Cyrus ^e   Fu, Xin ^a   Chen, Yuqin ^a   Yun, Xin ^a   Zhang, Jie ^a   Li, Meichan ^a   Xu, Lei ^d   Tang, Haiyang ^b   Yuan, Jason X J ^b   Wang, Jian ^a,b,c   Sun, Dejun ^c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Department of Ultrasound Medicine   (China)

^d The Affiliated Hospital of Inner Mongolia Medical University   (China)

^e GEISINGER MEDICAL CENTER   (United States)

Author keywords

PKG; PPAR ; SOCE; STS; TRPC

Indexed keywords

CALCIUM ION; CYCLIC GMP DEPENDENT PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL INTERFERING RNA; SODIUM TANSHINONE IIA SULFONATE; SULFONIC ACID DERIVATIVE; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; PHENANTHRENE DERIVATIVE; PPAR GAMMA, RAT; PROTEIN KINASE INHIBITOR; TANSHINONE II A SODIUM SULFONATE; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY C, MEMBER 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; GENE SILENCING; HYPOXIA-INDUCED PULMONARY HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; RAT; STORE OPERATED CALCIUM ENTRY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CALCIUM SIGNALING; CELL CULTURE; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HYPERTENSION, PULMONARY; HYPOXIA; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; TIME FACTOR; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE;

ANIMALS; CALCIUM SIGNALING; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION, PULMONARY; HYPOXIA; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENANTHRENES; PPAR GAMMA; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TRPC CATION CHANNELS; VASCULAR REMODELING;

EID: 84983683589     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00252.2015     Document Type: Article

References (49)

1. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF. Peroxisome proliferator- activated receptor gamma (PPAR gamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92: 1162–1169, 2003.
2. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54: S78–S84, 2009.
3. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122: 164–172, 2010.
4. Chattergoon NN, D’Souza FM, Deng W, Chen H, Hyman AL, Kadowitz PJ, Jeter JR Jr. Antiproliferative effects of calcitonin gene-related peptide in aortic and pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 288: L202–L211, 2005.
5. Chen IS, Dai ZK, Welsh DG, Chen IJ, Wu BN. Protein kinases modulate store-operated channels in pulmonary artery smooth muscle cells. J Biomed Sci 18: 2, 2011.
6. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A. Pulmonary arterial hypertension quality enhancement research initiative. I. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 71: 249–252, 2012.
7. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292: L885–L897, 2007.
8. Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 220: 3–10, 2012.
9. Gauthier A, Vassiliou G, Benoist F, McPherson R. Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J Biol Chem 278: 11945–11953, 2003.
10. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 118: 1846–1857, 2008.
11. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100: 15712–15717, 2003.
12. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9: 1491–1497, 2003.
13. Huang YF, Liu ML, Dong MQ, Yang WC, Zhang B, Luan LL, Dong HY, Xu M, Wang YX, Liu LL, Gao YQ, Li ZC. Effects of sodium tanshinone II A sulphonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro. J Ethnopharmacol 125: 436–443, 2009.
14. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645–650, 1990.
15. Jernigan NL, Resta TC. Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation. Am J Physiol Lung Cell Mol Physiol 282: L1366–L1375, 2002.
16. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 139: 1285–1293, 2011.
17. Kim EK, Lee JH, Oh YM, Lee YS, Lee SD. Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats. Respirology 15: 659–668, 2010.
18. Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E, Tomaselli GF, Kass DA. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol 48: 713–724, 2010.
19. 2+ signaling. Am J Physiol Heart Circ Physiol 302: H1546–H1562, 2012.
20. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 123: 993–999, 2005.
21. Li M, Li Z, Sun X, Yang L, Fang P, Liu Y, Li W, Xu J, Lu J, Xie M, Zhang D. Heme oxygenase-1/p21WAF1 mediates peroxisome proliferator-activated receptor-gamma signaling inhibition of proliferation of rat pulmonary artery smooth muscle cells. FEBS J 277: 1543–1550, 2010.
22. Li M, Sun X, Li Z, Liu Y. Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signaling in pulmonary artery smooth muscles cells. Pharm Res 59: 312–318, 2009.
23. Lu W, Ran P, Zhang D, Peng G, Li B, Zhong N, Wang J. Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. Am J Physiol Cell Physiol 298: C114–C123, 2010.
24. 2+ responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 295: L104–L113, 2008.
25. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O’Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726–741, 2006.
26. Newton CS, Loukinova E, Mikhailenko I, Ranganathan S, Gao Y, Haudenschild C, Strickland DK. Platelet-derived growth factor receptorbeta (PDGFR-beta) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function. J Biol Chem 280: 27872–27878, 2005.
27. 2+ influx and contraction in rat pulmonary artery. Circ Res 89: 923–929, 2001.
28. Nisbet RE, Bland JM, Kleinhenz DJ, Mitchell PO, Walp ER, Sutliff RL, Hart CM. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 42: 482–490, 2010.
29. Provencher S, Granton JT. Current treatment approaches to pulmonary arterial hypertension. Can J Cardiol 31: 460–477, 2015.
30. Takahashi S, Lin H, Geshi N, Mori Y, Kawarabayashi Y, Takami N, Mori MX, Honda A, Inoue R. Nitric oxide-cGMP-protein kinase G pathway negatively regulates vascular transient receptor potential channel TRPC6. J Physiol 586: 4209–4223, 2008.
31. Thenappan T, Glassner C, Gomberg-Maitland M. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest 141: 642–650, 2012.
32. Vantler M, Caglayan E, Zimmermann WH, Baumer AT, Rosenkranz S. Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3′-kinase is important. J Biol Chem 280: 14168–14176, 2005.
33. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 → S transition in vascular smooth muscle cells. J Biol Chem 275: 22435–22441, 2000.
34. Wang H, Gao X, Zhang B. Tanshinone: an inhibitor of proliferation of vascular smooth muscle cells. J Ethnopharmacol 99: 93–98, 2005.
35. 2+ influx and release in normal and hypoxic pulmonary hypertension rats. Eur J Pharmacol 640: 129–138, 2010.
36. Wang J, Jiang Q, Wan L, Yang K, Zhang Y, Chen Y, Wang E, Lai N, Zhao L, Jiang H, Sun Y, Zhong N, Ran P, Lu W. Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol 48: 125–134, 2013.
37. Wang J, Lu W, Wang W, Zhang N, Wu H, Liu C, Chen X, Chen Y, Chen Y, Jiang Q, Xu L, Tian L, Ran P, Zhong N. Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients. J Thorac Dis 5: 169–172, 2013.
38. Wang J, Shimoda LA, Sylvester JT. Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol 286: L848–L858, 2004.
39. 2+ entry. Am J Physiol Lung Cell Mol Physiol 288: L1059–L1069, 2005.
40. 2+ in pulmonary arterial smooth muscle cells. Circ Res 98: 1528–1537, 2006.
41. Wang J, Yang K, Xu L, Zhang Y, Lai N, Jiang H, Zhang Y, Zhong N, Ran P, Lu W. Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKGPPARgamma axis. Am J Respir Cell Mol Biol 49: 231–240, 2013.
42. Wang Y, Lu W, Yang K, Wang Y, Zhang J, Jia J, Yun X, Tian L, Chen Y, Jiang Q, Zhang B, Chen X, Wang J. Peroxisome proliferatoractivated receptor gamma inhibits pulmonary hypertension targeting storeoperated calcium entry. J Mol Med 93: 327–342, 2015.
43. 2+ and nonselective cation channels. Am J Physiol Lung Cell Mol Physiol 289: L5–L13, 2005.
44. Wu WY, Yan H, Wang XB, Gui YZ, Gao F, Tang XL, Qin YL, Su M, Chen T, Wang YP. Sodium tanshinone IIA silate inhibits high glucose-induced vascular smooth muscle cell proliferation and migration through activation of AMP-activated protein kinase. PloS One 9: e94957, 2014.
45. Xu S, Liu P. Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat 23: 149–153, 2013.
46. Yang K, Lu W, Jiang Q, Yun X, Zhao M, Jiang H, Wang J. PPARgamma inhibits hypoxia-induced store-operated calcium entry by suppressing caveolin-1. Am J Respir Cell Mol Biol 53: 882–892, 2015.
47. Yang K, Jiang Q, Wang Z, Li M, Zhang Q, Lu W, Wang J. Mutual inhibitory mechanisms between PPARgama and Hif-1a: implication in pulmonary hypertension. Receptor Clin Investig 2: e626, 2015.
48. + channels by sodium tanshinone II-A sulfonate (DS-201) in porcine coronary artery smooth muscle cells. Eur J Pharmacol 598: 9–15, 2008.
49. Yu ZL, Wang JN, Wu XH, Xie HJ, Han Y, Guan YT, Qin Y, Jiang JM. Tanshinone IIA prevents rat basilar artery smooth muscle cells proliferation by inactivation of PDK1 during the development of hypertension. J Cardiovasc Pharmacol Ther 20: 563–571, 2015.